8th Intl Congress on Drug Therapy In HIV Infection

Conference Reports for NATAP


8th International Congress on Drug Therapy in HIV Infection November 12-16, 2006 Glasgow, Scotland

	Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naive patients (12/13/06) TMC125, Darunavir, and Predicting Rescue Failure: -- TMC125 runs into a resistance wall -- Once- vs twice-daily enfuvirtide, and predictors of failure -- Susceptibility to--and drug interactions with--darunavir -- Trizivir plus tenofovir after toxicity or failure (and nuke preexisting resistance & predicting failure) -- Drug breaks with loads above 400 up risk of later rebound - Written for NATAP by Mark Mascolini (12/12/06) Fosamprenavir/r 1400/100 Once Daily Looks Promising - Written for NATAP by Mark Mascolini (12/07/06) Tipranavir 500/100 or 200 vs Kaletra in Naives - Written for NATAP by Mark Mascolini (12/07/06) SQV/r vs Kaletra, Gemini Study - Written for NATAP by Mark Mascolini (12/07/06) Boosted PIs and Other First-Line Strategies - Written for NATAP by Mark Mascolini (12/07/06) PK, Efficacy and Safety of Lopinavir/r + Atazanavir Without Nukes in Art Experienced (12/01/06) Optimal Kaletra Adherence During 1st Few Weeks on HAART Key To Achieving Viral Suppression (12/01/06) Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir (11/29/06) Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone (11/29/06) Three More Looks at First-Line Efavirenz vs Lopinavir - Written for NATAP by Mark Mascolini (11/29/06) Fixed Dose, Single Pill Truvada Preferred to TDF+FTC (11/28/06) The Safety And Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) Through 5 Years in Antiretroviral-naive Patients (11/28/06) Tenofovir/FTC+Efavirenz Compared to Combivir+Efavrienz, Safety & Efficacy at 96 Weeks. 934 Study (11/28/06) Gene Screening Lowers Rate of Abacavir Reaction - Written for NATAP by Mark Mascolini (11/28/06) Response to TMC114 is Based on Genotypic/Phenotypic Resistance: POWER 1/2/3 pooled analysis (11/28/06) Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline (11/28/06) Lack of Sex Differences in Once Daily Lopinavir/ritonavir Pharmacokinetic Profile (11/28/06) A PILOT 48-WEEK STUDY OF ONCE-DAILY (180 MG QD) VERSUS TWICE-DAILY (90 MG BID) ENFUVIRTIDE (11/28/06) Genetic Screening Test for Abacavir Hypersensitivity -- PREDICT-1: Description of a Novel Randomised Prospective Study Design to Determine the Clinical Utility of Prognostic Screening for HLA-B*5701 (11/28/06) More Details on Renal and Bone Toxicity With Tenofovir - Written for NATAP by Mark Mascolini (11/28/06) Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment-experienced patients (11/28/06) Week 48 efficacy of TPV/r treatment is enhanced in patients with higher numbers of genotypically available background drugs in RESIST 1 and 2 (11/27/06) Hypertension in HIV (11/27/06) Kaletra Tablets Improve Adherence, Tolerability, Diarrhea, and Side Effects Regardless of Ethnicity. Survey of 332 Patients: Blacks, Whites, Hispanics (11/27/06) Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir after switching from BID soft-gel capsule (SGC) to BID Tablets (11/27/06) Antilipid Tactics, Diabetes, and Abacavir Reactions: (1) prescribe a lipid lowering drug or switch to NNRTI; (2) Atazanavir, lipids, and cardiovascular risk; (3) antilipid drug rosuvastatin; (4) Diabetes risk factors in D:A:D: d4T, ddI, AZT increase risk, nevirapine protective; (5) abacavir genetic testing prevents hypersensitivity reaction - Written for NATAP by Mark Mascolini (11/27/06) Tenofovir Renal Affects in Mild Renal Impairment and Hypertension/Diabetes (11/21/06) Kaletra Tablets Improve Tolerability/Diarrhea Compared to Soft-Gel Capsules (11/21/06) Study Reports No Frequent Reporting of TMC125 Neurological or Psychiatric Events (11/20/06) Saquinavir/r 500mg Pills Once or Twice Daily: efficacy, lipids, ALT (11/20/06) Lipids & ALTs in SQV 500mg in Spanish Study (11/20/06) SQV 500mg (1000/100) in Exp/Naives (11/20/06) Switching to Saquinavir 500-mg Based Regimens in ART-Experienced (11/20/06) Trough Concentrations in HIV patients Receiving Boosted Hard-Gel Capsules (HGC) and 500 mg Film-Coated Tablet (FCT) Formulations of Saquinavir (11/20/06) Boosted Saquinavir Does Not Affect Methadone (11/20/06) Once Daily Fosamprenavir/RTV 1400/100mg + FD ABC/3TC Pilot study (11/17/06) TMC114 PK & Drug Interactions (11/17/06) Tipranavir 500/100 & 500/200 vs Kaletra in Naives (11/17/06) Tipranavir 500/100, 500/200 vs Kaletra in Naives (11/17/06) TMC125 in combination with other medications: summary of drug-drug interactions (11/17/06) No Higher Risk of Toxicity-Related ART Stops in Older People - Written for NATAP by Mark Mascolini (11/16/06) Treatment Breaks With >400 Copies Raise Risk of Later Rebound - Written for NATAP by Mark Mascolini (11/16/06) More Ribavirin, Longer Course Control HCV Better in HIV Patients - Written for NATAP by Mark Mascolini (11/16/06) Maraviroc, Changes in CD4 & Tropism in ART-EXperienced 1029 Study (11/16/06) What's Better for High Lipids: Antilipid Drugs or NNRTI Switch? (11/16/06) Antiretrovirals May be Double-Edged Sword for Liver Fibrosis: glucose levels associated with advancing fibrosis and increased CD4 count associated with slower fibrosis progression - Written for NATAP by Mark Mascolini (11/16/06) The Metabolic Syndrome at Baseline in the D:A:D study 20% (11/15/06) d4T and Lipodystrophy Raise Diabetes Risk in D:A:D Cohort; Nevirapine Protects - Written for NATAP by Mark Mascolini (11/15/06) First-Line Lopinavir Versus Efavirenz in Two European Studies - Written for NATAP by Mark Mascolini (11/15/06) Atazanavir Switch Improved Lipids But Limited Impact on Cardiovascular Risk Score; Should Intervene with Other Risk Factors - Written for NATAP by Mark Mascolini (11/15/06) Impact of NNRTI and NRTI Resistance on the Response to the Regimen of TMC125 Plus 2 NRTIs in Study TMC125-227 (11/14/06) TMC125 Controversial Response in Early Study - Written for NATAP by Mark Mascolini (11/14/06) Nonnucleoside Levels High in HIV-Infected Cirrhotics - Written for NATAP by Mark Mascolini (11/14/06) Resistance Rates on the Wane in Southern Europe - Written for NATAP by Mark Mascolini (11/14/06) SAQUINAVIR/R BID VS. LOPINAVIR/R BID PLUS FTC/TENOFOVIR QD IN ARV-NAIVE HIV-1 INFECTED PATIENTS: GEMINI STUDY (11/14/06) Ritonavir Boosted Saquinavir 1000/100 twice daily vs Kaletra: Preliminary Study Report After 24 Weeks - Written for NATAP by Mark Mascolini (11/14/06) Trizivir Maintenance After Efavirenz vs Lopinavir Induction - Written for NATAP by Mark Mascolini (11/14/06)